- Home
- PLSE vs COLL Comparison
PLSE vs COLL Comparison
Compare PLSE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | COLL |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PLSE | COLL |
|---|---|---|
| Price | $25.37 | $45.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $22.00 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 404.9K | 285.3K |
| Earning Date | 05-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.28 |
| Revenue | N/A | ★ $631,449,000.00 |
| Revenue This Year | N/A | $26.17 |
| Revenue Next Year | $1,250.20 | $3.65 |
| P/E Ratio | ★ N/A | $35.30 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $23.23 |
| 52 Week High | $26.30 | $50.79 |
Technical Indicators
Market Signals| Indicator | PLSE | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 71.93 | 43.73 |
| Support Level | $22.93 | $43.99 |
| Resistance Level | $25.80 | $46.66 |
| Average True Range (ATR) | 2.17 | 1.46 |
| MACD | 0.78 | -0.14 |
| Stochastic Oscillator | 91.60 | 20.21 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.